Skip to content
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact

How will the drug behave in the complex, unpredictable real world?

For decades, randomized clinical trials have been the gold standard for demonstrating a potential new medicine is safe and effective. Nowadays, however, payers, policymakers and suffering patients are demanding more.

As the research and healthcare landscape shifts towards increasing personalisation of treatment, rising emergence of rare diseases and earlier access, it is simultaneously grappling with the challenges posed by the high costs and lengthy timelines of delivering medicines to patients. Real world evidence has the potential to help facilitate access and address some of this burden, whilst also providing a better understanding of medicines use in the ‘real world’.

In which patients it will be most effective? How does it compare with other treatments? How cost-effective is it? How much will it cost to treat everyone who needs it?

Rather than just looking at the effects of the drug in a controlled (RCT) environment, we need understand what happens in actual clinical practice and use that to inform treatment and reimbursement decisions.

Through big data we can now find a better understanding of how prescription drugs are being used by physicians and patients in clinics, hospitals and patients’ homes across the world.

Read the Publications:

September 4, 2018

Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness

May, 2018

Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable

“Real-world data gives us the opportunity to bring the safest, most effective treatments to market and to ensure that the patients who can benefit the most have access to and are receiving those treatments today.”
Graeme McFarlane
Graeme McFarlaneChief Commercial Officer

Accelerated patient access pathway

The FDA is now focused on identifying additional areas in which RWE may be used to generate evidence of a therapy’s effectiveness. The FDA continue to encourage the use of RWE to drive for far richer, far more diverse, and more informative evidence. 

In England, the National Institute for Health and Care Excellence (NICE) appraises the clinical and cost-effectiveness of newly approved therapies and issues recommendations for public coverage in the National Health Service (NHS)

A representative of everyday clinical practice

RWE can provide a window into how therapies perform differentially across endpoints and subpopulations and against expectations. In essence, understanding the real-world performance of individual therapies allows for the development of better product profiles and performance thresholds to inform the payer value conversation.

Let us tell you more.

We will email you to start the conversation.

The impact of real world data

Real-World Data (RWD) are data relating to patient health status
and/or the delivery of health care routinely collected from a variety of sources. These sources provide reliable evaluations on three pillars of RWE Studies.

RWE analytics delivers valuable information, from the frontline of healthcare systems. This data leads the conversation with payers, healthcare providers, and regulators to make more holistic, rational healthcare decisions.

Improved data collection enables safer studies with significantly larger study populations whilst upholding gold standard patient care and integration.

Learn more

Humanistic data, typically focused on quality of life measures important to patients.

Clinical data, which helps evaluate a drug’s safety and effectiveness.

Economic data, used to evaluate its value.

accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.

Facebook
Twitter
Linkedin
Youtube
Envelope
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
Menu
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact

© 2021 Albert Labs. All Rights Reserved

Canada – 6996, Merritt Ave, Burnaby, BC, V5J 4R6 | United kingdom – 21 Marylebone High St, Unit 6, Marylebone, London W1U 4PE

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok